Suppr超能文献

α-L-艾杜糖苷酸酶酶活性测定的米氏动力学标准化。

Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics.

机构信息

Department of Genetics, Cell Biology and Development, PWB 13-146, 516 Delaware Str SE, Minneapolis, MN 55455, USA; Molecular, Cellular, Developmental Biology & Genetics Graduate Program, PWB 13-146, 516 Delaware Str SE, Minneapolis, MN 55455, USA; Gene Therapy Center, Department of Pediatrics, University of Minnesota, USA.

Department of Biochemistry, Molecular Biology and Biophysics, 5-120 NHH, 312 Church Str SE, Minneapolis, MN 55455, USA; Gene Therapy Center, Department of Pediatrics, University of Minnesota, USA.

出版信息

Mol Genet Metab. 2014 Feb;111(2):113-5. doi: 10.1016/j.ymgme.2013.11.009. Epub 2013 Nov 26.

Abstract

The lack of methodological uniformity in enzyme assays has been a long-standing difficulty, a problem for bench researchers, for the interpretation of clinical diagnostic tests, and an issue for investigational drug review. Illustrative of the problem, α-L-iduronidase enzyme catalytic activity is frequently measured with the substrate 4-methylumbelliferyl-α-L-iduronide (4MU-iduronide); however, final substrate concentrations used in different assays vary greatly, ranging from 25 μM to 1425 μM (Km ≈ 180 μM) making it difficult to compare results between laboratories. In this study, α-L-iduronidase was assayed with 15 different substrate concentrations. The resulting activity levels from the same specimens varied greatly with different substrate concentrations but, as a group, obeyed the expectations of Michaelis-Menten kinetics. Therefore, for the sake of improved comparability, it is proposed that α-L-iduronidase enzyme assays should be conducted either (1) under substrate saturating conditions; or (2) when concentrations are significantly below substrate saturation, with results standardized by arithmetic adjustment that considers Michaelis-Menten kinetics. The approach can be generalized to many other enzyme assays.

摘要

酶测定缺乏方法学的一致性一直是一个长期存在的难题,不仅给实验研究人员带来困扰,也为临床诊断测试的解释和药物研究带来了问题。以α-L-艾杜糖苷酸酶的酶催化活性的测定为例,该酶的活性通常用底物 4-甲基伞形酮-α-L-艾杜糖苷(4MU-iduronide)来进行检测;然而,不同测定方法中最终使用的底物浓度差异很大,范围从 25 μM 到 1425 μM(Km≈180 μM),这使得不同实验室之间的结果难以进行比较。在本研究中,使用了 15 种不同的底物浓度来对α-L-艾杜糖苷酸酶进行检测。尽管来自相同标本的活性水平随不同的底物浓度而有很大差异,但作为一个整体,它们符合米氏动力学的预期。因此,为了提高可比性,建议在以下两种情况下进行α-L-艾杜糖苷酸酶的酶测定:(1)在底物饱和条件下进行;(2)当浓度明显低于底物饱和时,通过考虑米氏动力学的算术调整对结果进行标准化。这种方法可以推广到许多其他酶的测定中。

相似文献

1
Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics.
Mol Genet Metab. 2014 Feb;111(2):113-5. doi: 10.1016/j.ymgme.2013.11.009. Epub 2013 Nov 26.
2
Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Mol Genet Metab. 2013 Aug;109(4):377-81. doi: 10.1016/j.ymgme.2013.05.016. Epub 2013 Jun 4.
5

引用本文的文献

2
Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice.
Mol Ther Methods Clin Dev. 2025 Jan 2;33(1):101405. doi: 10.1016/j.omtm.2024.101405. eCollection 2025 Mar 13.
5
Synthesis of Os@ZIF-8 nanocomposites with enhanced peroxidase-like activity for detection of Hg.
RSC Adv. 2024 Mar 26;14(14):9996-10003. doi: 10.1039/d3ra08723a. eCollection 2024 Mar 20.
6
Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system.
Mol Genet Metab Rep. 2022 Sep 18;33:100917. doi: 10.1016/j.ymgmr.2022.100917. eCollection 2022 Dec.
7
In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease.
Nat Commun. 2021 Jul 13;12(1):4291. doi: 10.1038/s41467-021-24443-8.
9
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
Biomolecules. 2021 Jan 29;11(2):189. doi: 10.3390/biom11020189.
10
Emerging Approaches for Fluorescence-Based Newborn Screening of Mucopolysaccharidoses.
Diagnostics (Basel). 2020 May 11;10(5):294. doi: 10.3390/diagnostics10050294.

本文引用的文献

1
Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.
Mol Genet Metab. 2012 May;106(1):131-4. doi: 10.1016/j.ymgme.2012.02.006. Epub 2012 Feb 10.
2
Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I.
Bone Marrow Transplant. 2012 Sep;47(9):1235-40. doi: 10.1038/bmt.2011.239. Epub 2011 Dec 19.
3
Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.
Neurobiol Dis. 2011 Jul;43(1):123-33. doi: 10.1016/j.nbd.2011.02.015. Epub 2011 Mar 17.
5
A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
Mol Ther. 2010 Feb;18(2):334-42. doi: 10.1038/mt.2009.236. Epub 2009 Oct 20.
6
Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system.
Mol Ther. 2009 Jul;17(7):1136-44. doi: 10.1038/mt.2009.87. Epub 2009 Apr 21.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验